CD274 and non-small cell squamous lung carcinoma: An indirect comparison of patients with advanced squamous non-small cell lung cancer showed that, for patients with low/negative PDL-1 expression, pembrolizumab had superior OS (HR 0.43, 95% CI 0.24–0.76; p < 0.01/HR 0.74, 95% CI 0.40–1.38; p = 0.35) and better progression-free survival (HR 0.80, 95% CI 0.51–1.26; p = 0.33/HR 0.46, 95% CI 0.28–0.75; p < 0.01) than atezolizumab [47].